Arcturus Therapeutics (NASDAQ:ARCT) Posts Earnings Results, Beats Expectations By $0.06 EPS

Arcturus Therapeutics (NASDAQ:ARCT) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.06, FiscalAI reports. The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• Arcturus has begun enrollment in a 12-week open‑label Phase II of ARCT‑032 for Class 1 cystic fibrosis and reports patients have tolerated continuous inhaled dosing beyond one month, which the company attributes to its proprietary LUNAR delivery lipids and mRNA purification process.
• After a Type C meeting with the FDA, ARCT‑810 (OTC deficiency) received clear regulatory direction toward a pivotal pediatric development path; Arcturus is collecting additional exploratory data and plans an end‑of‑Phase II meeting in H2 2026.
• Financially, Arcturus reported $213.4 million in cash as of March 31, 2026 and says its cash runway extends beyond Q2 2028 following cost reductions and a strategic refocus on rare disease programs, despite a year‑over‑year revenue decline tied to reduced collaboration income.
• Partner Meiji is actively manufacturing Arcturus’ self‑amplifying mRNA COVID vaccine KOSTAIVE for Japan’s 2026/2027 season and will provide all commercial guidance, leaving Arcturus’ near‑term commercial exposure dependent on the partner.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT traded up $0.32 during mid-day trading on Friday, reaching $9.22. 931,599 shares of the stock were exchanged, compared to its average volume of 469,249. The business’s 50 day moving average is $7.89 and its 200-day moving average is $7.83. Arcturus Therapeutics has a 1 year low of $5.85 and a 1 year high of $24.17. The company has a market capitalization of $262.03 million, a P/E ratio of -3.87 and a beta of 2.43.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ARCT. ARK Investment Management LLC boosted its holdings in Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after buying an additional 738,378 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Arcturus Therapeutics by 1,371.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock worth $10,177,000 after buying an additional 514,652 shares in the last quarter. Millennium Management LLC purchased a new position in Arcturus Therapeutics during the first quarter valued at $4,892,000. Bank of America Corp DE lifted its holdings in Arcturus Therapeutics by 112.0% during the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Arcturus Therapeutics by 170.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company’s stock valued at $2,398,000 after purchasing an additional 246,499 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ARCT. B. Riley Financial began coverage on shares of Arcturus Therapeutics in a research note on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings upgraded shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. Citigroup cut their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Piper Sandler lowered their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Finally, Roth Mkm started coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.50.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.